Please login to the form below

Not currently logged in
Email:
Password:

Savient

This page shows the latest Savient news and features for those working in and with pharma, biotech and healthcare.

AZ moves a step closer to gout drug approval in US

AZ moves a step closer to gout drug approval in US

Another recent entrant into the market - Savient Pharmaceuticals - was unable to make headway with its Krystexxa (pegloticase) therapy and was forced to file for bankruptcy in 2013.

Latest news

  • AZ files gout drug lesinurad in Europe AZ files gout drug lesinurad in Europe

    Another recent entrant into the gout market - Savient Pharmaceuticals - was forced to file for bankruptcy in 2013 after poor sales of its gout therapy Krystexxa (pegloticase).

  • Phase III data back AZ's gout drug Phase III data back AZ's gout drug

    On the other hand, another recent entrant into the market - Savient Pharmaceuticals - was forced to file for bankruptcy last year on lacklustre sales of its gout therapy Krystexxa (pegloticase).

  • Good news for AZ on gout candidate lesinurad Good news for AZ on gout candidate lesinurad

    Another company with high expectations - Savient Pharma - was forced to file for bankruptcy protection in October after sales of its gout treatment Krystexxa (pegloticase) remained stubbornly low despite being launched in

  • Savient faces bankruptcy after Krystexxa sales disappoint Savient faces bankruptcy after Krystexxa sales disappoint

    According to Reuters, Savient listed total assets of about $74m and liabilities of $260m as of June 30. ... Stephen Jaeger, chairman of the board of Savient, explained that filing for bankruptcy and agreeing to sell company assets was “the best

  • Novartis and Savient face NICE rejections Novartis and Savient face NICE rejections

    On the same day that drugs for blood clot and diabetes were recommended for NHS use in England and Wales, healthcare authorities rejected medicines from Novartis and Savient. ... The National Institute for Health and Care Excellence (NICE), which

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics